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Abstract: Human coronaviruses represent a significant disease burden; however, there is currently no
antiviral strategy to combat infection. The outbreak of severe acute respiratory syndrome (SARS) in
2003 and Middle East respiratory syndrome (MERS) less than 10 years later demonstrates the potential
of coronaviruses to cross species boundaries and further highlights the importance of identifying
novel lead compounds with broad spectrum activity. The coronavirus 3CLpro provides a highly
validated drug target and as there is a high degree of sequence homology and conservation in main
chain architecture the design of broad spectrum inhibitors is viable. The ZINC drugs-now library was
screened in a consensus high-throughput pharmacophore modeling and molecular docking approach
by Vina, Glide, GOLD and MM-GBSA. Molecular dynamics further confirmed results obtained
from structure-based techniques. A highly defined hit-list of 19 compounds was identified by the
structure-based drug design methodologies. As these compounds were extensively validated by a
consensus approach and by molecular dynamics, the likelihood that at least one of these compounds
is bioactive is excellent. Additionally, the compounds segregate into 15 significantly dissimilar
(p < 0.05) clusters based on shape and features, which represent valuable scaffolds that can be used as
a basis for future anti-coronaviral inhibitor discovery experiments. Importantly though, the enriched
subset of 19 compounds identified from the larger library has to be validated experimentally.
Keywords: human coronaviruses; molecular docking; 3CLpro; virtual screening; structure-based
drug design; molecular dynamics
1. Introduction
Coronaviruses (CoV) affect a diverse group of animal hosts, and cause a plethora of diseases
in animals including progressive peritonitis, acute and chronic hepatitis, gastroenteritis, nephritis,
and encephalitis [1]. In humans, coronavirus infection results in respiratory tract complications with
varying degree of severity and has been associated with gastroenteritis. Four human coronaviruses
(HCoV; 229E, OC43, NL63 and HKU1) are endemic in the human population and are mainly associated
with mild, self-limiting respiratory illnesses. Another two human coronaviruses, namely severe
acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV, cause
severe respiratory syndromes and present a significant threat with their high fatality rates. The
clinical presentation of the four non-severe, endemic, human coronaviruses is largely indistinguishable
symptomatically, commonly presenting with rhinorrhea, sore throat, cough and fever [2,3]. Majority
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of infections are associated with self-limiting upper respiratory tract disease or “the common
cold” but can also present with high morbidity outcomes of the lower respiratory tract including
bronchiolitis, pneumonia, [4–6], asthmatic exacerbations [7] acute exacerbations of chronic obstructive
pulmonary disease (COPD) [8] and croup in HCoV-NL63 infected patients [9], and commonly results in
hospitalization. Febrile seizures have been reported for most human coronaviruses but the significance
of HKU1 is alarming with one study indicating that 50% of patients infected with HKU1 experience
febrile seizures [7].
HCoVs affect all age groups [2,3] but elicit more serious disease in young, elderly and
immunocompromised [4,10,11], frequently resulting in hospitalization. Reports on the prevalence of
HCoVs and their association with upper and lower respiratory tract disease vary but range between
3.3% and 16% [2,3,10,12]. Over 70% of the general public has seroconverted towards all four non-severe
HCoVs with primary infection shown to occur in childhood [13] and reinfection occurring throughout
life [10]. Given the high prevalence of respiratory infections, human coronaviruses represent a
substantial disease burden, which is exacerbated by the high implications of healthcare workers in
coronavirus outbreaks [12].
The outbreak of SARS-CoV in 2003 and MERS-CoV less than 10 years later highlights an additional
significant threat of coronaviruses to humans and confirms that the SARS outbreak in 2003 was not
an isolated incident. With the ever increasing diversity of animal coronavirus species, especially
within bats, the likelihood of recombination leading to future outbreaks is high and the threat of
potential pandemics is real as highly pathogenic coronaviruses continue to spill over from zoonotic
sources into the human population. Misdiagnosis of these outbreaks pose a further substantial threat
to healthcare workers with nosocomial spread to other patients putting further pressure on an already
strained healthcare system. As there is currently no antiviral strategy to combat infection with human
coronaviruses [14], and supportive care is the primary treatment regime, the importance of identifying
broad spectrum lead compounds is increasing.
The 3CLpro has proven to be a valuable target in drug discovery efforts and has been validated
as an effective drug target in several studies. It has even been termed “the Achilles’ heel of
coronaviruses” [15]. A wide variety of inhibitor classes, including peptidomimetic analogues, covalent
inhibitors and small molecule inhibitors have been assessed. These compounds have been identified
by ab initio structure-based design, high throughput and virtual screening [15,16], where inhibitors
either target the enzyme active site or the allosteric dimerization domain [17,18]. The first generation
of 3CLpro inhibitors were irreversible peptidomimetic structures, often five residues in length with
at reactive warhead at the terminus that formed a covalent bond between the thiolate anion of the
catalytic Cys145 residue and the reactive atom of the warhead [19]. These reactive warheads have
included Michael acceptors [20–22], aldehydes [23], epoxy-ketones [24], halo-methyl ketones [25],
and trifluoromethyl ketones [26]. Peptide derivative warhead inhibitors were later followed by the
development of non-peptidic covalent inhibitors [27,28]. The use of covalent inhibitors is however
limited due there propensity for off-target side-effects and toxicity [29]. Recent studies have therefore
focused more on the development of noncovalent inhibitors, which have generally produced large
peptidomimetic compounds with low ligand efficiency [19] and currently there is still no effective
therapy for the treatment of HCoVs [14]. All coronavirus 3CLpro share a high sequence homology, as
well as main chain architecture and substrate conservation [30,31], which makes the identification of
broad spectrum lead compounds more viable.
The substrate binding site of the 3CLpro has two deeply buried S1 and S2 subsites, as well as shallow
S11 , S3 and S4 subsites with varying degrees of solvent exposure. Substrate specificity of coronavirus
3CLpro is mainly determined by the P1, P2 and P11 positions [31]. The P1 position has an absolute specificity
for glutamine which stabilizes the S1 subsite via a hydrogen bond with the imidazole Nε2 of His162/3
and van der Waals interactions with surrounding residues of the S1 pocket. The P2 site has a preference for
leucine or methionine to fill the hydrophobic S2 pocket. The sidechains of the S3 site are solvent-exposed
and therefore this site is expected to tolerate a wide range of functionality, but shows a preference for basic
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residues [32]. Sidechains and backbones of residues surrounding the S4 site create a highly congested
pocket which favors a small, hydrophobic residue in the P4 position, either Ser, Thr, Val or Pro [32–34].
The S11 and S21 subsites also accommodate small residues in the P11 and P21 positions, which may include
Ser, Ala or Gly [33,35]. A typical cleavage recognition site is therefore (Ser, Ala)-(Val, Thr)-Leu-Glu Ó (Ser,
Ala, Gly), which is conserved among all coronavirus 3CLpro [36]. These features can therefore be exploited
in the design of potential broad spectrum lead compounds.
2. Materials and Methods
2.1. Consensus Docking and Scoring with Vina, Glide, Gold and Molecular Mechanics-Generalized Born
Surface Area (MM-GBSA)
Crystal structures of the 3CLpro for 229E, NL63, HKU1 and SARS-CoV were obtained from
PDB. The 3CLpro of OC43 was obtained by homology modeling [37]. Vina performed the initial
high throughput screen of the Drugs-Now dataset from ZINC, comprising a total of approximately
6.5 million compounds. Ligand files were obtained in 3D SDF format and converted to PDB with Open
Babel [38]. Ligand PDB files were then converted to PDBQT with the prepare_ligand4.py script.
The initial virtual screen was conducted with 2ZU2 (3CLpro of HCoV-229E) as the receptor as
it comprises the largest binding pocket and therefore should identify the largest amount of primary
leads. The bound ligands of apo structures were removed to create an appropriate cavity within the
binding site. For docking with Vina, the receptor was processed with Autodock Tools [39] where
water molecules were removed and polar hydrogens and Gasteiger charges were added. Histidine
was protonated in the neutral state at the epsilon nitrogen (Nε2) in accordance with crystal data. The
grid box for searching was centered on the active His41 residue with grid box spacing set to 1 Å and
extended 26 grid points in each direction to encompass the entire binding pocket. The top ranked
1500 ligands from the virtual screen formed the primary hit-list as this was an acceptable quantity
for the medium throughput analysis and subsequent refinement. The lowest binding score within
the hit-list corresponded to a binding affinity of ´9.5 kcal/mol and therefore all compounds with an
equivalent binding affinity were progressed.
For docking and later refinement with Glide the 3CLpro structures were prepared in Maestro with
Schrödinger’s Protein Preparation Wizard. Receptors were minimized by a restrained minimization
using the OPLS2005 force field [40,41], during which, heavy atoms were restrained to remain within
0.3 Å of the original structure. To define the binding site for docking with Glide, each structure
was aligned and an active inhibitor (obtained from the crystal structure of the HKU1 3CLpro) was
superimposed over the active site. For docking in Glide the receptor grid was generated around the
superimposed ligand to accurately encompass the binding pocket. The grid box was generated 10 Å
in each direction and a constraint was set for the ligand to form a hydrogen bond with the pivotal
His162 residue of the S1 active pocket. All other settings remained default to Glide receptor grid
generation. Glide docking was performed with default settings using standard precision (SP) mode
with the fulfilment of the previously defined constraint. Ligands which did not fulfil this constraint
were automatically excluded. A binding score cut-off, defined as ´7 kcal/mol, was used to further
filter the hit-list. This cut-off was predetermined based on the binding affinity of a known inhibitor.
Filtered compounds were subsequently imported into GOLD for redocking into the 2ZU2 structure
prepared in Maestro where the active site was again defined by superimposition of the active ligand.
An automated docking procedure with default parameters were used including 50 docking attempts
and clusters defined by heavy atoms of ligands separated by >0.75 Å root-mean-square deviation
(RMSD). The GOLDScore fitness scoring function was used to rank ligands based on a GOLDScore
cut-off of 60 [42]. To ensure an accurate prediction of binding pose, the RMSD between the poses
predicted by Vina, Glide and GOLD were measured using the rmsd.py script of Schrödinger. Ligands
where the RMSD was greater than 2 Å between predicted poses were excluded.
The Prime/MM-GBSA method was used to calculate the binding free energy of each ligand within
the docking complex, where the pose predicted by Glide was utilized. The free energy of binding
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is the calculated difference between the minimized receptor-inhibitor complex and the sum of the
energies of the minimized unbound inhibitor and receptor. Ligand poses were minimized using the
local optimization feature in Prime, where energies of the complex were calculated with the OPLS-2005
force field and GBSA continuum solvent model. As a final filter a binding free energy cut-off of
´80 kcal/mol was defined by determining the free energy of binding of a known active inhibitor.
2.2. Pharmacophore Model for VS
Pharmacophore tools of Molecular Operating Environment (MOE) [43] were used to define 3D
pharmacophoric features using the 3IH ligand and 3D23 structure for the initial high throughput virtual
screen. Features included an essential hydrogen bond with the His163 residue and a hydrophobic
moiety in the P2 position. Excluded volumes of 1 Å were set to better consider the steric effects.
Non-essential features included a hydrogen bond donor and acceptor in the Glu166 position, a
hydrogen bond acceptor in the P4 pocket, a single hydrogen bond donor in the P2 and P3 pocket
and an acceptor in the P11 pocket. A total of four pharmacophoric features were required within the
excluded volumes of 1 Å. The pharmacophore model again screened the Drugs-Now dataset. Ligands
satisfying the pharmacophore query within an RMSD of 0.5 Å were protonated with Open Babel and
steric clashes caused by the ligand in order to satisfy pharmacophore constraints in the absence of
explicit hydrogens were removed by refine only docking with Glide. A hydrogen bond constraint
with His163 was used as a primary filter. Compounds were immediately assessed with the MM-GBSA
scoring function, to avoid possible false negatives of the less reliable docking scoring functions, where
the previously described MM-GBSA cut-off of ´80 kcal/mol was again implemented.
2.3. Characterization of Broad Spectrum Potential
The above mentioned techniques conducted a high throughput virtual screen of the ZINC
Drugs-Now dataset by docking and pharmacophore modeling. The structure-based screen identified
potential binders of 2ZU2, where the ligand-based approach focused on 3D23. To identify which
of these compounds would potentially form broad spectrum inhibitors the remaining three 3CLpro
structures were incorporated into the study. All five structures were aligned and ligands identified by
docking and pharmacophore modeling were superimposed over individual active sites. Side chains
of residues in the active pocket assuming orientations that resulted in a steric clash with the ligand
were refined and the ligand was minimized with Prime to better fit the pocket. MM-GBSA methods
described previously were again applied to predict the free binding energy of the complex. As before,
a binding energy of ´80 kcal/mol was used as a cut-off and the hydrogen bond constraint in the S1
pocket was again applied to discriminate between potential binders and non-binders. In an effort to
not miss potential leads the interpretation of certain parameters were left flexible if other parameters
supported the advancement of the compound.
2.4. Molecular Dynamic Simulation
The CHARMM27 all atom force field was assigned to receptor structures using the three point
TIP3P water model. All input hydrogens in the coordinate file were ignored and were assigned
according to the force field. Histidine protonation states were assigned to the epsilon nitrogen in the
neutral form in accordance with crystallographic data. The ligand, in the pose predicted by molecular
docking, was prepared by SwisParam [44]. The protein-ligand complex was then placed in the center of
a solvated, cubic box, 1 nm from the box edge. The system was solvated with the spc216 water model
and sodium counter ions were added to neutralize the system. The system was energy minimized by a
brief dynamics simulation using Steepest Descent Minimization until steepest descent converged to
Fmax <1000. Long range electrostatic interactions were calculated with the Particle Mesh Ewald (PME)
method [45] with a cutoff of 1 nm and periodic boundary conditions were applied. Both NVT and NPT
equilibrations were run for 50,000 steps or 100 ps using a 2 fs time step and a leap-frog integrator. All
bonds were constrained by the LINCS algorithm. PME was again used for long range electrostatics
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with a 0.16 Fourier spacing. Short range electrostatic and van der Waals cutoffs were 1.0 nm and
1.4 nm respectively. Coordinates, velocities and energies were saved every 0.2 ps. During NVT
equilibration temperature coupling was achieved by V-rescale algorithm with a target temperature of
300 K. Pressure coupling during NPT equilibration was achieved via the Parrinello-Rahman algorithm
and is incorporated in the NPT equilibration once temperature is stable to ensure the proper density is
reached (approximately 1000 kg/m3). Following NVT and NPT system equilibration an unrestrained,
10 ns simulation (5,000,000 steps) was run with the leap frog integrator, saving coordinates, velocities
and energies every 2 ps. All other parameters were maintained from the NVT and NPT equilibration
including both temperature and pressure coupling.
3. Results
3.1. Starting Structures
The 3CLpro of 229E was previously solved in complex with an inhibitor by X-ray crystallography
at a high resolution of 1.8 Å [46]. The corresponding crystallographic structure, with Protein Data Bank
(PDB) code 2ZU2, shows a dimeric structure with the inhibitor, zinc N-ethyl-N-phenyldithiocarbamate
(EPDTC), coordinated to the catalytic dyad residues of His41 and Cys144 with a zinc-centered
tetrahedral geometry. The apo form of the NL63 3CLpro was solved in its dimeric form by X-ray
crystallography to a high resolution of 1.6 Å with the respective PDB code, 3TLO. The HCoV-NL63
3CLpro structure (3TLO) however remains unpublished in any academic journals. Recently, our group
solved and published the 3CLpro structure of OC43 by homology modeling [37].
The PDB code, 3D23, represents the structure of the 3CLpro of HKU1. It was previously solved by
X-ray crystallography to a resolution of 2.5 Å in complex with a peptidomimetic, covalent inhibitor [30].
The PDB entry contains a total of four chains, two chains form the active dimeric structure with the
remaining two found in monomeric forms. Each chain contains the covalent inhibitor bound to the active
site which undergoes nucleophilic attack of the active cysteine Sγ to form an irreversible, covalent bond.
As this inhibitor possesses several pharmacophoric features common to the natural substrate and favorable
to drug development it was utilized to develop a pharmacophore model for virtual screening.
There are several structures available which represent the SARS-CoV 3CLpro. However, the
majority of these include structures in complex with a peptidomimetic, covalent inhibitor [46–48]
or mutational studies [49–51]. At the time this study commenced, only one structure could be
identified in complex with a small molecule inhibitor. This structure, with PDB code 3V3M [19],
also represented the only coronavirus 3CLpro with a noncovalent inhibitor. As this structure could
be used for necessary benchmarking in latter studies, it was chosen to represent the SARS-CoV
3CLpro. The crystallographic structure contains a noncovalent, furyl amide ligand, ML188, which was
identified by a high throughput screen, with subsequent lead optimization based on structure-activity
relationships within the S1, S11 and S2 binding pockets.
3.2. Defining Benchmarks and Determining Accuracy of Vina and Glide
Molecular docking algorithms are often calibrated on a training set of experimental ligand-protein
complexes and accuracy of these docking programs is often highly dependent on the training set used [52].
This highlights the importance of confirming that the docking software used for virtual screening is
capable of replicating the binding mode of a known, experimental inhibitor for the class of enzymes
studied [53,54].
In order to confirm that the molecular docking algorithms used in this study are well suited to
the 3CLpro of human coronaviruses, and their related class, a previously solved experimental structure
with a bound, noncovalent inhibitor is required. Accurate replication of the experimental binding pose
by molecular docking will confirm the suitability of the docking algorithm for virtual screening. Initial
studies on structure-based design of inhibitors, targeting the 3CLpro of coronaviruses, were focused
on peptidomimetic compounds with a reactive warhead group that formed an irreversible, covalent
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interaction with the active Cys residue [19]. These large, covalent inhibitors would be incompatible
with molecular docking as replication of the quantum mechanics necessary for covalent bond formation
is outside the capabilities of molecular docking [55]. From the PDB several experimental structures
of the 3CLpro of various species of coronaviruses with bound inhibitor could be identified. Almost
all of these structures represented large, peptidomimetic, covalent inhibitors, with the exception of
3V3M [19]. The structure of 3V3M represented the only noncovalent inhibitor of modest size that we
could identify from the PDB. Replication of the binding mode of the bound inhibitor, ML188, by the
docking algorithms used in the virtual screen and subsequent refinement process would indicate that
they are well calibrated for this class of receptor.
Default parameters applied to the high throughput virtual screen for Vina and refinement
with Glide were applied to the inhibitor and receptor of 3V3M. An RMSD below 2 Å for heavy
atoms (excluding hydrogens) between the experimental structure and predicted pose of docking is a
well-defined benchmark to assess the accuracy of molecular docking sampling algorithms [56]. Figure 1
represents the experimental pose of the ML188 ligand with overlaid predicted pose of Vina and Glide.
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of 0.79 Å (Figure 1b). This indicates that sampling by both Vina and Glide are well calibrated for the 
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Figure 1. The pose of an experimental ligand, ML188, as predicted by Vina and Glide. (a) Experimental
orientation of ML188 (green) with overlaid pose predicted by Vina (blue); (b) Experimental orientation
of ML188 (green) with overlaid pose predicted by Glide (blue). An root-mean-square deviation (RMSD)
of 0.244 Å for Vina and 0.79 Å for Glide suggests that they are well calibrated for this class of enzyme
and should achieve a high level of accuracy in predicting the pose of novel ligands.
Vina was able to accurately predict the pose of ML188, where the top ranked pose was within
an RMSD of only 0.244 Å to the experimental structure within the pocket of 3V3M (Figure 1a). The
orientation of the P11 furan is somewhat distorted with the conformation of the ring structure being
assumed to orientate at a right angle to the experimental pose. The overall predicted pose of Vina
corresponds to the experimental pose with a high level of accuracy. Glide was also capable of accurately
predicting the pose of ML188 within the pocket of 3V3M within an RMSD of 0.79 Å (Figure 1b). This
indicates that sampling by both Vina and Glide are well calibrated for the class of enzyme studied and,
as the remaining structures are highly homologous to 3V3M, they will achieve an equivalent level of
accuracy. These results strongly support the use of Vina as high throughput tool for virtual screening
and indicates that with the use of Glide as a subsequent refinement tool, the accuracy of predicting the
binding pose of novel ligands will be high.
The ML188 lead compound also provided a means to set benchmarks for scoring functions and
free energy of binding estimation. The inhibitor achieved a binding affinity estimation of´8.1 kcal/mol
when bound to 3V3M. In an effort to reduce the numbers of false negatives this value was decreased to
´7 kcal/mol for filtering purposes. For MM-GBSA scoring it is advisable that the threshold value is
defined by an experimental structure [57]. The highly homologous structure of 3V3M with the known
active inhibitor ML188 was therefore scored with MM-GBSA. The free energy of binding between
3V3M and ML188, where ligand strain was taken into account, was equal to ´85 kcal/mol. As this
ligand is highly suited towards the structure of 3V3M, where our goal is the identification of broad
spectrum inhibitors, the cut-off value was decreased to ´80 kcal/mol. This was done to ensure that
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ligands with potential broad spectrum activity were not missed based on their predicted inability to
bind to a single receptor.
3.3. Molecular Docking
Vina was chosen as the tool to conduct the initial high throughput screen of the approximately
6.5 million compounds of the Drugs-Now dataset of the ZINC database. For the initial screen, 2ZU2
was selected as the receptor to identify the highly refined subset of potential inhibitors. This receptor
possessed the largest binding pocket of all structures when analyzed by SiteMap (data not shown) and
it was therefore proposed to provide the largest number of initial hit compounds. The primary hit-list
consisted of the top 1500 ranked compounds from the high throughput virtual screen (HTVS) of the
ZINC Drugs-Now dataset conducted by Vina, a quantity where further refinement and analysis would
be achievable. Ranking the initial virtual screen based on docking score alone serves as a starting point
in the selection criteria and assumes that the predicted binding affinity somewhat reflects true binding
affinity [58–60]. The lowest binding score within this hit-list corresponded to ´9.5 kcal/mol. Scoring
functions have shown success in differentiating between binders and non-binders [61] by ranking the
binding score. For this reason, all ligands which achieved this score were also included in the study,
yielding a total of 1527 hit compounds. Further assessment and refinement of this initial hit-list of 1527
ligands was conducted by redocking with Glide and GOLD and scoring with their respective scoring
functions and MM-GBSA.
To improve the likelihood of identifying actual active compounds, three sampling algorithms and
four scoring functions were applied to the hit-list identified by Vina in a consensus based approach.
This approach has frequently improved enrichment rates of active compounds in a virtual screening
context, in comparison to the use of a single algorithm for docking and scoring [62–64]. The initial
stage of refinement included redocking with Glide under standard precision and rescoring with its
internal Glide GScore scoring function. In order to define a threshold binding score cut-off to prefilter
hits, the crystallographic structure of 3V3M, with bound inhibitor ML188, was used. As most scoring
functions cannot be compared between structures it is important to define a binding score cut-off based
on a related experimental structure [57]. The inhibitor ML188 achieved a binding affinity estimation
of ´8.1 kcal/mol when bound to 3V3M. In an effort to reduce the numbers of false negatives this
value was decreased to ´7 kcal/mol. As a subsequent stage of hit-list refinement the identified hit
compounds and 2ZU2 receptor were directly imported into GOLD for redocking and rescoring. A
GOLDScore Fitness cut-off was defined as 60 and again used to prefilter hits [42].
At this stage the hit-list was refined to a point where the binding pose of each hit could be
analyzed by manual inspection. The natural substrate of the 3CLpro forms a hydrogen bond with
His162/3 in the S1 pocket where the S2 pocket is filled by a hydrophobic moiety. Each ligand was
therefore assessed with the Pose Filter script of Schrödinger and manually in Maestro to confirm that
each ligand identified in the hit-list met these pharmacophoric constraints. These comprehensive
filters of three sampling and scoring algorithms and pharmacophoric feature constraints provided us
with a highly defined hit-list of 116 compounds. Assessing the free energy of binding with the highly
advanced MM-GBSA scoring function would provide further confidence that the hits identified do in
fact represent high-likelihood active compounds.
Rescoring the final hit-list with MM-GBSA identified a total of 22 ligands that passed all filters
and pharmacophoric constraints for the 2ZU2 receptor. This included a total of three sampling
algorithms and four scoring functions from Vina, Glide and GOLD and the highly advanced MM-GBSA,
respectively, and two pharmacophoric constraints with a hydrogen bond acceptor in the S1 pocket
and a hydrophobic moiety filling the S2 pocket. This consensus docking and scoring approach is
in comparison to several studies, which identified novel lead compounds from a virtual screen,
where only a single molecular docking algorithm was incorporated [65–69]. The comprehensive
list of techniques used in this study heightens the probability that the ligands identified in the final
hit-list do represent novel scaffolds of active molecules and with the high homology between the
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3CLpro of various human coronaviruses these compounds should exhibit a high potential for broad
spectrum effects.
3.4. Pharmacophore Modeling
Varying techniques in drug design have led to the identification of different ligands from the
same dataset and even identification of divergent scaffolds [70–72]. The use of multiple techniques
therefore improves the probability of identifying a diverse set of lead compounds. The pharmacophore
model was based largely on a single covalent inhibitor. This inhibitor was chosen as it possesses
several favorable noncovalent features for the generation of a pharmacophore model. As general
practice, several inhibitors are often used to generate a pharmacophore model where features that
are frequently repeated are included in the pharmacophore [73]. For 3CLpro these features are well
documented [32,70,71,74] and the presence of several active ligands would only serve to replicate
the prior knowledge. The essential features of the pharmacophore model included a hydrogen bond
acceptor in the P1 position and a hydrophobic moiety in the P2 position. Non-essential features
included a hydrogen bond donor and acceptor in the position to interact with Glu166, a hydrogen
bond acceptor in the P4 pocket, a single hydrogen bond donor in the P2 and P3 pockets and an acceptor
in the P11 pocket. A total of four features, including the two essential features and any two of the
non-essential features, within an excluded volume of 1 Å were required for a potential hit to satisfy the
pharmacophore model.
Molecular Operating Environment (MOE) was used to generate the pharmacophore model and
conduct the virtual screen against the entire ZINC Drugs-Now dataset. To ensure a primary hit-list
of manageable size, only ligands satisfying the pharmacophore within an RMSD of 0.5 Å where
filtered to the initial hit-list, which included approximately 25,000 compounds. Since MOE utilizes
a united atom force field, it was necessary to add hydrogens with Open Babel. The protonation of
the ligands generated several steric clashes within the active pocket of 3D23 and refine-only docking
with Glide was therefore used to remove these clashes. As the pharmacophore model only filters
compounds based on the presence of a hydrogen bond acceptor in the P1 position, and does not take
into account distance and geometry essential for the formation of a hydrogen bond, the Pose Filter
script of Schrödinger was again used to further refine the hit-list, which now contained 3569 hits.
Scoring this hit-list with MM-GBSA further reduced its size to 15 compounds with the previously
defined cut-off value.
3.5. Identification of Potential Broad Spectrum Inhibitors
The two virtual screening approaches, including molecular docking against 2ZU2, and
pharmacophore modeling with the active inhibitor of 3D23, provided us with 22 and 15 hits respectively.
Initial attempts to redock these hits into the individual binding pockets of the remaining four structures
in order to identify potential broad spectrum inhibitors proved highly unsuccessful. Neither the
binding mode nor binding affinity or free energy of binding could be replicated for any complex
studied. This finding was in contradiction to our hypothesis that the high degree of homology between
various active sites should allow for development of broad spectrum inhibitors.
The static nature of the receptor during docking did not allow for any degree of the induced-fit
phenomena, which is commonly observed during ligand or substrate binding [75]. Although the
residues within the active site of individual 3CLpro are highly homologous, the orientation of their
sidechains is variable between structures, which hinder ligand binding. In a dynamic, physiological
system, these sidechains would accommodate ligand binding by the induced-fit phenomena, however
in molecular docking this process is circumvented by the static nature of the receptor [76]. This was
the sole reason for the inability to replicate the binding mode, seen in 2ZU2 and 3D23, in the remaining
structures. The orientation of residue sidechains inserting into the active pocket were highly variable
and the inability to replicate the dynamic movements of these sidechains during docking led to the
highly variable and inefficient binding modes with decreased binding affinity.
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To overcome this short fall of molecular docking, each receptor was aligned and ligands were
superimposed over individual active sites using coordinates identified while docking to 2ZU2 or
refine-only docking with 3D23. Residue sidechains resulting in a steric clash with the ligand were
refined using the Prime module of Schrödinger, which replicates their dynamic, flexible movements
allowing the sidechains to accommodate the ligand in the pocket. The ligand was then minimized
within the pocket to remove any further steric clashes.
The binding mode predicted using this approach was then further assessed using the
pharmacophoric constraints of a hydrogen bond in the S1 and a hydrophobic moiety in the S2 pockets
and scoring with MM-GBSA where the cut-off previously defined was again implemented. Of the
22 compounds identified in the hit-list of potential 2ZU2 binders, 15 compounds could replicate the
interactions in the S1 and S2 pockets and fulfil the MM-GBSA cut-off (Table 1), where four of the
compounds identified by pharmacophore modeling could fulfil these requirements (Table 2). This
final list of 19 ligands represented 15 distinct clusters (Figure 2). Free energy of binding between a
known active inhibitor, ML188, and respective coronavirus 3CLpro is also shown in Tables 1 and 2 for
comparative purposes.
Table 1. Series of ligands identified by molecular docking with respective binding affinities and
root-mean-square deviation (RMSD) between predicted poses from individual sampling algorithms.
Initial virtual screen utilized 2ZU2 as the receptor. Binding affinity and mode was predicted by four
scoring functions and three sampling algorithms respectively. Broad spectrum potential was assessed
by scoring with molecular mechanics-generalized Born surface area (MM-GBSA).
ZINC ID
Binding Affinity in 2ZU2 RMSD
Vina-Glide
RMSD
Glide-GOLD
MM-GBSA of Remaining Structures
Vina Glide GOLD MM-GBSA 3V3M 3D23 3TLO OC43
27332786 ´9.5 ´7.43 73.75 ´89.4 1.69 1.58 ´100.8 ´106.1 ´95.8 ´96.4
20130947 ´9.5 ´9.04 74.43 ´83.6 0.03 0.045 ´90.1 ´96.0 ´88.4 ´87.7
15987063 ´9.8 ´8.34 68.43 ´82.3 6.89 0.007 ´91.0 ´91.1 ´79.3 ´87.3
02466851 ´9.5 ´8.92 75.65 ´100.3 7.14 0.01 ´98.0 ´104.3 ´79.7 ´89.8
12798320 ´9.6 ´8.18 72.81 ´89.5 1.48 0.006 ´83.0 ´97.4 ´79.7 ´94.3
09477134 ´9.6 ´7.72 75.80 ´86.0 4.09 0.005 ´98.0 ´88.4 ´77.3 ´84.1
32983195 ´9.5 ´7.02 65.44 ´82.7 0.98 2.27 ´81.6 ´79.4 ´73.1 ´77.8
09104621 ´9.8 ´7.33 70.91 ´83.3 1.20 0.002 ´79.6 ´100.6 ´69.4 ´87.7
02328322 ´9.7 ´8.53 75.37 ´81.8 0.94 0.01 ´89.2 ´85.5 ´73.8 ´83.7
12550995 ´9.5 ´8.92 74.56 ´81.4 1.62 0.01 ´93.1 ´84.1 ´74.2 ´78.7
12697660 ´9.5 ´7.68 75.08 ´90.4 7.76 0.001 ´94.1 ´88.1 ´62.4 ´77.7
11783131 ´9.6 ´8.30 73.74 ´84.0 6.74 0.01 ´97.9 ´80.1 ´75.3 ´87.7
12597223 ´9.5 ´9.00 68.90 ´81.8 4.48 0.004 ´76.7 ´81.1 ´68.7 ´75.4
15999133 ´9.7 ´8.00 69.40 ´81.9 6.22 0.003 ´79.0 ´97.1 ´70.1 ´91.5
35829976 ´9.6 ´8.33 70.23 ´80.2 6.10 0.01 ´70.0 ´92.2 ´60.9 ´79.0
ML188 ´7.9 ´8.1 N/A ´85.0 0.244 N/A ´83.1 ´85.2 ´78.5 ´85.3
Table 2. Free energy of binding as predicted by MM-GBSA for a series of ligands identified by
pharmacophore modeling, with known inhibitor ML188 as a reference.
ZINC ID
MM-GBSA
3D23 2ZU2 3V3M 3TLO OC43
09411012 ´85.2 ´84.6 ´81.9 ´77.5 ´90.9
02426719 ´103.0 ´80.7 ´85.5 ´73.7 ´109.3
02094118 ´83.3 ´90.8 ´69.8 ´82.8 ´102.8
09346433 ´92.5 ´79.2 ´81.9 ´63.1 ´103.4
ML188 ´85.2 ´77.4 ´83.1 ´78.5 ´85.3
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Figure 2. Division of the nineteen candidate ligands into fifteen distinct 3D clusters, as determined by 
the PubChem (https://pubchem.ncbi.nlm.nih.gov) structure-clustering web-service. 3D Tanimoto 
similarity scores were calculated from alignments generated using shape + feature and ten conformers 
per ligand. The dendogram was generated using similarity score of 1.04, which is recommended to 
achieve statistical significance at the 95% confidence interval. 
3.6. Molecular Dynamics 
Molecular dynamics utilizes Newtonian physics to simulate atomic movements in a solvated 
system and remains the most accurate computational method for simulating protein-drug 
interactions. To confirm the findings seen in docking and pharmacophore modeling and validate the 
binding mode of representative hit-compounds, a 10 ns molecular dynamic simulation allowed for 
an assessment of non-bonded energies and hydrogen bonding networks between ligand and receptor 
and ligand stability via RMSD, radius of gyration and changes in solvent accessible surface area. As 
molecular dynamic simulations are extremely computer intensive one representative ligand identified 
from molecular docking and one from pharmacophore modeling was used. The ability of molecular 
dynamic simulations to replicate the binding conformation and ligand stability would verify that the 
identified hit-list does in fact represent likely actives. 
3.6.1. Candidate Inhibitor Identified by Molecular Docking, ZINC27332786 
The conformation of the ZINC27332786 ligand, as identified by molecular docking results, 
indicated that it binds to the active site and forms similar key interactions throughout all five 
proteases studied. A pyridine filled the S1 pocket and formed a hydrogen bond between the pyridine 
nitrogen and imidazole Nε2 of His163. A 1,2,4-triazole formed a linker in the center of the structure 
and mediated the formation of a hydrogen bond between N2 and the backbone of Glu165/6, which 
formed a third hydrogen bond via the backbone carbonyl and ligand NH. OC43 3CLpro exhibited a 
fourth hydrogen bond between N4 of the 1,2,4-triazole and Gln189. This residue is conserved in 3D23 
and 3V3M structures, however it was orientated towards the solvent exposed exterior of the pocket. 
In 2ZU2 and 3TLO the position of Gln is replaced by Pro188/9, which therefore did not contribute to 
the formation of a bond. Two 2-chloro-6-fluorobenzyl rings also filled the hydrophobic S2 and S4 
pockets (Figure 3). 
Figure 2. Division of the nineteen candidate ligands into fifteen distinct 3D clusters, as determined
by the PubChem (https://pubchem.ncbi.nlm.nih.gov) structure-clustering web-service. 3D Tanimoto
similarity scores were calculated from alignments generated using shape + feature and ten conformers
per ligand. The dendogram was generated using similarity score of 1.04, which is recommended to
achieve statistical significance at the 95% confidence interval.
3.6. Molecular Dynamics
Molecular dynamics utilizes Newtonian physics to simulate atomic movements in a solvated
system and remains the most accurate computational method for simulating protein-drug interactions.
To confirm the findings seen in docking and pharmacophore modeling and validate the binding mode
of representative hit-compounds, a 10 ns molecular dynamic simulation allowed for an assessment
of non-bonded energies and hydrogen bonding networks between ligand and receptor and ligand
stability via RMSD, radius of gyration and changes in solvent accessible surface area. As molecular
dynamic simulations are extremely computer intensive one representative ligand identified from
molecular docking and one from pharmacophore modeling was used. The ability of molecular
dynamic simulations to replicate the binding conformation and ligand stability would verify that the
identified hit-list does in fact represent likely actives.
3.6.1. Candidate Inhibitor Identified by olecular Docking, ZINC27332786
The conformation of the ZINC27332786 ligand, as identified by molecular docking results,
indicated that it binds to the active site and forms similar key interactions throughout all five proteases
studied. A pyridine filled the S1 pocket and formed a hydrogen bond between the pyridine nitrogen
and imidazole Nε2 of His163. A 1,2,4-triazole formed a linker in the center of the structure and
mediated the formation of a hydrogen bond between N2 and the backbone of Glu165/6, which formed
a third hydrogen bond via the backbone carbonyl and ligand NH. OC43 3CLpro exhibited a fourth
hydrogen bond between N4 of the 1,2,4-triazole and Gln189. This residue is conserved in 3D23 and
3V3M structures, however it was orientated towards the solvent exposed exterior of the pocket. In
2ZU2 and 3TLO the position of Gln is replaced by Pro188/9, which therefore did not contribute to the
formation of a bond. Two 2-chloro-6-fluorobenzyl rings also filled the hydrophobic S2 and S4 pockets
(Figure 3).
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Figure 3. Pose of the ZINC27332786 ligand within the active site of the 3CLpro. Representation of 
elements mediating hydrogen bonds with respective residues and the P1 pyridine, hydrophobic P2 
and P4 and a 1,2,4-triazole linker. 
Molecular dynamics studies indicated that for 3V3M all these interactions were highly 
conserved, forming an average of three bonds over the simulation with high occupancies between 
His163 and both bonds at Glu166. The remaining four structures exhibited similar profiles however 
with varying degrees of occupancy, with an average bond formation of 2.5 for 2ZU2, 1.7 for 3D23,  
2.6 for 3TLO and 2.1 for OC43 3CLpro. All structures displayed high occupancy at both Glu166 
positions, however a decreased occupancy at the His162/3 position. OC43 3CLpro and 3D23 observed 
the lowest occupancy of 13.63% and 7.27% respectively and 2ZU2 and 3TLO displayed moderate 
occupancies of 25.30% and 41.05% respectively. The loss of hydrogen bond formation at this position 
was often caused by the pyridine ring orientating at a right angle to the His162/3 Nε2. With the 
exception of 3TLO all structures also formed hydrogen bonds with moderate frequency with 
Gln191/2. These bonds were predominantly formed via the backbone, however 2ZU2 was capable of 
forming with both the backbone and sidechain, where the sidechain exhibits a higher frequency. The 
bond formed between Glu189 and the N4 of the 1,2,4-triazole, as seen in docking results for OC43 
3CLpro, exhibits a relatively low occupancy of 17.95%. 
This indicated that results achieved from molecular dynamics were in relatively strong 
agreement with that of molecular docking, where all bonds were formed with high frequency, with 
the exception of the bond between the pyridine N and His162/3, which remained present, however 
at lower occupancy. The compound does, however, still provide an excellent scaffold for lead 
optimization with the substructures filling the S2, S3 and S4 subsites making extensive and  
stable interactions with surrounding residues including two hydrogen bonds between the central 
1,2,4-triazole and NH and the backbone of Glu165/6. Further lead optimization may explore the 
replacement of the pyridine ring with the related lactam ring, which is known to mediate two 
hydrogen bonds, one between the ligand carbonyl and the His162/3 Nε2 and a second hydrogen bond 
between the lactam NH and Glu166 [46]. The presence of this second hydrogen bond and van der 
Waals interactions, mediated via ring substituents, may further stabilize the compound within the S1 
pocket. A phenylalanine substituent or imidazole ring, has also shown to improve the inhibitory 
effects of peptidomimetic inhibitors [47,77]. 
Analysis of ligand RMSD indicated that all structures deviated to some extent from their starting 
structures at the beginning of the simulation, but once in this position were stable and only minor 
fluctuations were observed from this point. Solvent accessible surface area of the ligand also 
remained consistent throughout the duration of the simulation and fluctuated within a range  
of 4.8 nm2–5.4 nm2 (Figure 4). Assessment of ligand radius of gyration also indicated that  
the compactness of the ligand did not alter greatly during the 10 ns simulation and fluctuated  
within 4.6 Å and 4.9 Å for all structures. This again indicated that the ligand is stable within the 
pocket and did not dissociate into surrounding solvent. 
Figure 3. Pose of the ZINC27332786 ligand within the active site of the 3CLpro. Representation of
elements mediating hydrogen bonds with respective residues and the P1 pyridine, hydrophobic P2 and
P4 and a 1,2,4-triazole linker.
Molecular dynamics studies indicated that for 3V3M all these interactions were highly conserved,
forming an average of three bonds over the simulation with high occupancies between His163 and
both bonds at Glu166. The remaining four structures exhibited similar profiles however with varying
degrees of occupancy, with an average bond formation of 2.5 for 2ZU2, 1.7 for 3D23, 2.6 for 3TLO and
2.1 for OC43 3CLpro. All structures displayed high occupancy at both Glu166 positions, however a
decreased occupancy at the His162/3 position. OC43 3CLpro and 3D23 observed the lowest occupancy
of 13.63% and 7.27% respectively and 2ZU2 and 3TLO displayed moderate occupancies of 25.30%
and 41.05% respectively. The loss of hydrogen bond formation at this position was often caused
by the pyridine ring orientating at a right angle to the His162/3 Nε2. With the exception of 3TLO
all structures also formed hydrogen bonds with moderate frequency with Gln191/2. These bonds
were predominantly formed via the backbone, however 2ZU2 was capable of forming with both the
backbone and sidechain, where the sidechain exhibits a higher frequency. The bond formed between
Glu189 and the N4 of the 1,2,4-triazole, as seen in docking results for OC43 3CLpro, exhibits a relatively
low occupancy of 17.95%.
This indicated that results achieved from molecular dynamics were in relatively strong agreement
with that of molecular docking, where all bonds were formed with high frequency, with the exception
of the bond between the pyridine N and His162/3, which remained present, however at lower
occupancy. The compound does, however, still provide an excellent scaffold for lead optimization
with the substructures filling the S2, S3 and S4 subsites making extensive and stable interactions with
surrounding residues including two hydrogen bonds between the central 1,2,4-triazole and NH and
the backbone of Glu165/6. Further lead optimization may explore the replacement of the pyridine
ring with the related lactam ring, which is known to mediate two hydrogen bonds, one between the
ligand carbonyl and the His162/3 Nε2 and a second hydrogen bond between the lactam NH and
Glu166 [46]. The presence of this second hydrogen bond and van der Waals interactions, mediated
via ring substituents, may further stabilize the compound within the S1 pocket. A phenylalanine
substituent or imidazole ring, has also shown to improve the inhibitory effects of peptidomimetic
inhibitors [47,77].
Analysis of ligand RMSD indicated that all structures deviated to some extent from their starting
structures at the beginning of the simulation, but once in this position were stable and only minor
fluctuations were observed from this point. Solvent accessible surface area of the ligand also remained
consistent throughout the duration of the simulation and fluctuated within a range of 4.8 nm2–5.4 nm2
(Figure 4). Assessment of ligand radius of gyration also indicated that the compactness of the ligand
did not alter greatly during the 10 ns simulation and fluctuated within 4.6 Å and 4.9 Å for all
structures. This again indicated that the ligand is stable within the pocket and did not dissociate into
surrounding solvent.
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Figure 4. Pose of the ZINC09411012 ligand within the active site of the 3CLpro. Representation of 
elements mediating hydrogen bonds with respective residues and the P1 pyridine, hydrophobic P2 
and solvent exposed dioxolane. 
3.6.2. Candidate Inhibitor Identified by Pharmacophore Modeling, ZINC09411012 
The 3CLpro structures with bound inhibitor identified by pharmacophore modeling again 
indicated conserved interactions between the receptor and ligand. As with the previous compound a 
pyridine ring fills the S1 pocket and formed a hydrogen bond with the imidazole Nε2 of His162/3.  
A backbone carbonyl of His164 for 3V3M formed a hydrogen bond with a ligand NH. This residue 
was replaced by a Gln in all remaining structures, however a backbone carbonyl of these two residues 
were perfectly aligned thereby allowing the formation of the hydrogen bond in all structures. The 
backbone NH of Glu165/6 again formed a hydrogen bond with a ligand carbonyl. A fourth hydrogen 
bond is observed in 3V3M, 3D23 and OC43 3CLpro between the sidechain of Gln189 and a ligand 
carbonyl. The position of this Gln in 2ZU2 and 3TLO was not aligned structurally to 3V3M, 3D23 or 
OC43 3CLpro, with structural superimposition showing a Pro in this position accounting for the loss 
of the hydrogen bond in 2ZU2 and 3TLO. Two methyl groups insert into the deep S2 pocket and made 
extensive hydrophobic interactions with surrounding residues. A potential problematic feature of 
this ligand was a solvent exposed 1,3-dioxolane, which made few interactions with surrounding 
residues. Further lead optimization steps may explore the removal of this substituent to ascertain any 
structure-activity relationship (Figure 5). 
 
Figure 5. Destabilization of ZINC09411012 from the 2ZU2 active site. (a) Starting conformation where 
the pyridine fills the S1 pocket and forms a hydrogen bond with His162; (b) Initial destabilization 
resulting in the break of the hydrogen bond with His162 and subsequent formation with Ala143; (c) 
Further destabilization resulting a new hydrogen bond with Gly142; (d) Complete loss of orientation. 
Molecular dynamics trajectories again showed a strong correlation with that seen in our 
pharmacophore models, with the exception of the 2ZU2-ZINC09411012 complex. In this structure the 
pyridine ring gradually dissociated out of the S1 pocket at around 4 ns followed by almost complete 
dissociation of the ligand from the active site, where the 1,3-dioxolane became completely solvent 
exposed. The two methyl groups that filled the hydrophobic S2 pocket remained the only 
Figure 4. Pose of the ZINC09411012 ligand within the active site of the 3CLpro. Representation of
elements mediating hydrogen bonds with respective residues and the P1 pyridine, hydrophobic P2 and
solvent exposed dioxolane.
3.6.2. Candidate Inhibitor Identified by Pharmacophore Modeling, ZINC09411012
The 3CLpro structures with bound inhibitor identified by pharmacophore modeling again
indicated conserved interactions between the receptor and ligand. As with the previous compound a
pyridine ring fills the S1 pocket and formed a hydrogen bond with the imidazole Nε2 of His162/3.
A backbone carbonyl of His164 for 3V3M formed a hydrogen bond with a ligand NH. This residue
was replaced by a Gln in all remaining structures, however a backbone carbonyl of these two residues
were perfectly aligned thereby allowing the formation of the hydrogen bond in all structures. The
backbone NH of Glu165/6 again formed a hydrogen bond with a ligand carbonyl. A fourth hydrogen
bond is observed in 3V3M, 3D23 and OC43 3CLpro between the sidechain of Gln189 and a ligand
carbonyl. The position of this Gln in 2ZU2 and 3TLO was not aligned structurally to 3V3M, 3D23
or OC43 3CLpro, with structural superimposition showing a Pro in this position accounting for the
loss of the hydrogen bond in 2ZU2 and 3TLO. Two methyl groups insert into the deep S2 pocket and
made extensive hydrophobic interactions with surrounding residues. A potential problematic feature
of this ligand was a solvent exposed 1,3-dioxolane, which made few interactions with surrounding
residues. Further lead optimization steps may explore the removal of this substituent to ascertain any
structure-activity relationship (Figure 5).
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Molecular dynamics trajectories again showed a strong correlation with that seen in our 
pharmacophore models, with the exception of the 2ZU2-ZINC09411012 complex. In this structure the 
pyridine ring gradually dissociated out of the S1 pocket at around 4 ns followed by almost complete 
dissociation of the ligand from the active site, where the 1,3-dioxolane became completely solvent 
exposed. The two methyl groups that filled the hydrophobic S2 pocket remained the only 
Figure 5. Destabilization of ZINC09411012 from the 2ZU2 active site. (a) Starting conformation where
the pyridine fills the S1 pocket and forms a hydrogen bond with His162; (b) Initial destabilization
resulting in the break of the hydrogen bond with His162 and subsequent formation with Ala143;
(c) Further destabilization resulting a new hydrogen bond with Gly142; (d) Complete loss of orientation.
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Molecular dynamics trajectories again showed a strong correlation with that seen in our
pharmacophore models, with the exception of the 2ZU2-ZINC09411012 complex. In this structure the
pyridine ring gradually dissociated out of the S1 pocket at around 4 ns followed by almost complete
dissociation of the ligand from the active site, where the 1,3-dioxolane became completely solvent
exposed. The two methyl groups that filled the hydrophobic S2 pocket remained the only substructures
of the ligand to maintain any structural conformation in the active subsite, indicating the importance
of this group in ligand stability. The orientation of all S1 subsite residues including His162, Phe139,
Glu165, His171 and Tyr160 remained unaltered and therefore could not attribute to this loss of stability.
The movement may most likely be attributed to by an initial minor loss of stability caused by the
movement of Ala143 closer to the pyridine ring, with subsequent bond formation between the Ala
backbone and pyridine N. This movement destabilized the pyridine ring, which subsequently formed
a new hydrogen bond with Gly142. At this point the pyridine had almost completely lost its orientation
in the S1 pocket, which resulted in further loss of the van der Waals interactions leading to complete
dissociation from the pocket (Figure 5). This movement also corresponded to a gradually increasing
RMSD, assuming few stable conformations, indicative of an unstable ligand.
The position of Ala143 in 2ZU2 is transformed to Ser in 3V3M, 3D23 and OC43 3CLpro, suggesting
that the hydrophobic sidechain of the Ala in 2ZU2 may have promoted the movement towards the
pyridine, encouraging rotation of the nitrogen towards the Ala backbone. The orientation of the
pyridine ring in 3TLO is somewhat stabilized by a bifurcated interaction with the sidechain of Glu166
which promoted the movement of the pyridine N away from Ala143 without disrupting the interaction
with His162. Lead optimization steps may therefore preferentially incorporate a core structure that
prevents rotation of the pyridine by resulting steric clashes. As mentioned previously, the exploration
of a phenylalanine substituent, imidazole or lactam ring in this position may also contribute positively
to the stability of the ligand within the S1 pocket [46,47,77].
The remaining structures did however show stability of the ligand within the active pocket, where
the occupancy of the hydrogen bond with the Nε2 of His162/3 ranged from 64% for 3TLO, 75% for
OC43 3CLpro, 83% for 3V3M and 89% for 3D23. Interactions with the Glu165/6 were also highly
conserved with a frequency of 86% for 3TLO, 91% for OC43 3CLpro and 3V3M and 94% for 3D23. The
position of 164, occupied by a His in 3V3M and a Gln in the remaining structures, showed varying
degrees of bond formation, with the presence of the His in 3V3M resulting in a significant reduction in
bond formation. Gln showed moderate, 41% for 3D23, to high, 88% for 3TLO, occupancy with OC43
3CLpro having an occupancy of 61%. The sidechain of Gln189 was shown to form a hydrogen bond
with the ligand in 3V3M, 3D23 and OC43 3CLpro, however this residue was highly solvent exposed and
therefore resulted in a high degree of flexibility of the sidechain, which should hinder the formation of
this bond. For 3D23 and OC43 3CLpro this was observed, where the frequency of bond formation was
27% and 6% respectively. In 3V3M the ligand was however able to stabilize the sidechain to maintain
the formation of the bond with a high degree of frequency at 73%.
Ligand RMSD again showed similar profiles to the previously described complexes, where
initially a large movement was observed followed by subsequent stabilization of the ligand within
the active site. Structures, including 3V3M and 3D23, observed significant fluctuations within their
stable conformation which was largely attributed to by the presence of the solvent exposed dioxolane
moiety, which had few features and interactions to stabilize it within the pocket. As this structure
contributed few interactions, future studies may explore the removal of this substituent to ascertain its
effects on stability. Radius of gyration again confirmed RMSD results where all structures fluctuate
between 4.7 Å and 5.0 Å, with the exception of 2ZU2 which deterred greatly at approximately 6 ns
that signified the point at which the pyridine ring completely dissociated from the S1 pocket. This
however did not result in an increase in solvent accessible surface area where all structures fluctuated
between 3.8 nm2 and 4.4 nm2. With the exception of 2ZU2, these structures confirmed, with great
confidence, the interactions and conformations observed within our rigid pharmacophore model.
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The representative ligand identified by molecular docking was also able to largely fulfil the interactions
and orientations observed.
4. Discussion
Lead compounds that have shown promise as potential inhibitors of the 3CLpro of coronaviruses
are largely represented by peptidomimetic compounds that covalently alter the thiolate anion of
the active Cys residue [19]. These compounds are generally large and have a high likelihood of off
target effects through covalent modification and, as yet, there remains no commercially available
molecular entity for the treatment of coronaviruses [14]. Few studies have focused on the development
of broad spectrum, noncovalent inhibitors and, to our knowledge, none have aimed to prioritize the
identification of broad spectrum lead compounds that inhibit the 3CLpro related to the coronaviruses
that most frequently affect humans, namely 229E, OC43, NL63 and HKU1. For this reason, there is
insufficient knowledge surrounding the structure of broad spectrum inhibitors targeting this family of
proteases. This study, focusing on these and the coronavirus associated with SARS, provides valuable
insight into the structure of ligand scaffolds of potential noncovalent inhibitors.
Different techniques used in virtual screening have led to the identification of a diverse set of lead
compounds, where one technique is able to identify compounds the other may have missed [70,71].
For this reason, we used a joint docking and pharmacophore modeling based virtual screening strategy
to identify a highly defined list of potential lead compounds. Molecular docking and pharmacophore
modeling are extremely useful tools in the design and identification of novel lead compounds and have
relatively low infrastructure and fiscal dependence. Its importance in the pharmaceutical industry
cannot be overlooked even though it does have several shortcomings. Fundamental flaws in these
structure-based techniques include the static nature of the receptor and the implicit solvent models
used for virtual screening. Molecular dynamics is the most advanced in silico tool, which allows us
to fill this void by incorporating Newtonian physics to simulate the dynamic movements of proteins
in an explicit solvent model thereby replicating the native environment of the protein. Molecular
dynamic simulations also provide a mechanistic explanation for any ligand inactivity, which would
be impossible to identify with in vitro techniques. In this study, it has identified the key feature
responsible for the destabilization of the ZINC09411012 ligand within the 2ZU2 binding pocket
and thereby allowed us to identify which substituents should be replaced in further rounds of lead
optimization. As ligand inactivity may be a result of a single misplaced substituent this mechanistic
view point provides extensive information for future lead optimization.
The essential pharmacophoric constraints, including an acceptor in the P1 and hydrophobic
moiety in P2, used in both docking and pharmacophore modeling drug discovery methods would
be expected to generate a hit-list with similar scaffolds. The final hit-list, containing a total of
19 ligands (15 from molecular docking and four identified by pharmacophore modeling), however
were highly divergent and represented 15 distinct clusters. These were determined using the
PubChem (https://pubchem.ncbi.nlm.nih.gov) structure clustering web-service with shape + feature
3D similarity and recommended parameters for achieving statistical significance at the 95% confidence
interval (Figure 5). 3D similarity calculation, using shape-only and feature-only, yielded similar results
(data not shown). As all cluster members were already preselected for features to fill the P1 and P2
pockets, have similar estimated binding affinities and the structure clusters are significantly dissimilar,
they represent 15 valuable scaffolds that can be further experimentally validated and to be used as a
basis for future lead optimization and anti-coronaviral inhibitor discovery experiments.
In our simulations of potential inhibitors, previously identified by structure and ligand-based
drug design techniques including molecular docking and pharmacophore modeling, we could largely
replicate all interactions observed in our static models. The pyridine ring that fills the S1 pocket in
3V3M is stable in both modelled ligand-protein complexes and with the known inhibitor, ML188, it is
evident that this feature contributes positively to antiviral effects of the inhibitor [19]. However, with
the remaining 3CLpro, several complexes showed instability of the pyridine ring within the S1 pocket.
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We therefore propose that future lead optimization explores the effects of incorporating a lactam ring in
this position as it is known to better replicate the interactions of the natural substrate and is also effective
against the SARS-CoV 3CLpro [46]. A phenylalanine substituent and an imidazole ring have also been
shown to be efficacious in this P1 position [47,77]. The replication of the majority of interactions that
were observed in the static structure-based models for ZINC27332786, from molecular docking, and
ZINC09411012, from pharmacophore modeling, suggests that the structure-based techniques were
correct in identifying the key interactions and orientation of the ligand within the pocket. We can
therefore confidently assume that the remaining ligands identified in the structure-based techniques
are, in fact, in their correct conformation and do represent promising lead compounds.
As the second generation of lead discovery focusing on non-peptidic, noncovalent inhibitors
is still largely in its infancy, future in vitro activity assays of the ligands identified in this study will
provide vital information on novel scaffolds for lead optimization. The diverse and comprehensive
approach of hit-list refinement also ensures a high likelihood of the presence of bioactives within
the list. This study provides a promising start in the pursuit of active lead compounds for the broad
spectrum inhibition of the 3CLpro associated with human coronaviruses. These results strongly support
further in vitro testing of this highly refined hit-list. Activity data will provide valuable information on
the structure of bioactive scaffolds and could represent the next generation of small lead molecules. In
conclusion, in the drug-design sphere, a variety of computational approaches have been used at the
various stages of the drug-design process in support of the experimental techniques. Structure-based
and ligand-based drug design approaches have developed into valuable drug discovery tools [78],
owing to their versatility and synergistic character [79]. Importantly, however, predictions from virtual
screening methods are not meant to replace experimental affinity determination, but can complement
the experimental methods by producing an enriched subset of a large chemical database, with an
increased possibility of the compounds actually binding to the drug target of interest [80,81]. Therefore,
since past research has shown that many predicted drug candidates fail to prove effective in vivo the
experimental validation of the identified 19 ligands reported in this manuscript is essential.
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